J&J's TREMFYA shows 94% clinical remission in Crohn's disease at three years

Johnson & Johnson's TREMFYA has shown consistent results in Crohn's disease, achieving 94% clinical remission at three years and 28% fistula remission versus 10% in placebo, according to a social media post.

Detected & updated continuously · Source: Nebula